The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer

Duttagupta, Sreya; Hakozaki, Taiki; Routy, Bertrand; Messaoudene, Meriem

doi:10.3390/curroncol30110681

Cited by 6 publications

(4 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite numerous studies having analyzed various potential biomarkers for predicting responses and irAEs, few of them have shown potential with certain limitations for selecting patients who will best benefit from the therapy [ 26 ]. The immunological response is modulated not only by the local tumoral lesion but also by various parts of the body, including the gut (the focus of our study), where local and systemic immune responses are modulated by a close dialogue with the microbiota [ 27 , 28 ]. The various factors of the host gut microenvironment that have been proposed to modulate the immune response against tumors and, specifically, the response to ICIs in lung cancer include the microbiota and, less explored, SCFAs and epithelial barrier markers.…”

Section: Discussionmentioning

confidence: 99%

Biomarkers of Immunotherapy Response in Patients with Non-Small-Cell Lung Cancer: Microbiota Composition, Short-Chain Fatty Acids, and Intestinal Permeability

Moratiel-Pellitero,

Zapata-García,

Gascón-Ruiz

et al. 2024

Cancers

View full text Add to dashboard Cite

Immune checkpoint inhibitors have been proposed as the standard treatment for different stages of non-small-cell lung cancer in multiple indications. Not all patients benefit from these treatments, however, and certain patients develop immune-related adverse events. Although the search for predictors of response to these drugs is a major field of research, these issues have yet to be resolved. It has been postulated that microbiota could play a relevant role in conditioning the response to cancer treatments; however, the human factor of intestinal permeability also needs to be considered as it is closely related to the regulation of host–microbiota interaction. In this article, we analyzed the possible relationship between the response to immune checkpoint inhibitors and the onset of immune-related adverse events, gut microbiota status, and intestinal membrane permeability. In a pioneering step, we also measured short-chain fatty acid content in feces. Although the correlation analyses failed to identify predictive biomarkers, even when all variables were integrated, our patients’ microbial gut ecosystems were rich and diverse, and the intestinal barrier’s integrity was preserved. These results add new knowledge on the composition of microbiota and its correlation with barrier permeability and short-chain fatty acids and suggest that more studies are required before these potential biomarkers can be incorporated into the clinical management of patients via immune checkpoint inhibitor treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Biomarkers of Immunotherapy Response in Patients with Non-Small-Cell Lung Cancer: Microbiota Composition, Short-Chain Fatty Acids, and Intestinal Permeability

Moratiel-Pellitero,

Zapata-García,

Gascón-Ruiz

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Among the well-known biomarkers, such as PDL1 and the PD1-PDL1 axis, TMB (tumor mutational burden), and others, the microbiota potentially appears to be the most relevant predictor of immunotherapeutic efficacy. There are many factors that can influence and modulate the microbiota, and all of them could play an important role in cancer development as well as in the efficacy and toxicity of immunotherapy [48,52].…”

Section: Future Directionsmentioning

confidence: 99%

Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC)

Del Giudice,

Staropoli,

Tassone

et al. 2024

Cancers

View full text Add to dashboard Cite

Despite the recent availability of immune checkpoint inhibitors, not all patients affected by Non-Small-Cell Lung Cancer (NSCLC) benefit from immunotherapy. The reason for this variability relies on a variety of factors which may allow for the identification of novel biomarkers. Presently, a variety of biomarkers are under investigation, including the PD1/PDL1 axis, the tumor mutational burden, and the microbiota. The latter is made by all the bacteria and other microorganisms hosted in our body. The gut microbiota is the most represented and has been involved in different physiological and pathological events, including cancer. In this light, it appears that all conditions modifying the gut microbiota can influence cancer, its treatment, and its treatment-related toxicities. The aim of this review is to analyze all the conditions influencing the gut microbiota and, therefore, affecting the response to immunotherapy, iRAEs, and their management in NSCLC patients. The investigation of the landscape of these biological events can allow for novel insights into the optimal management of NSCLC immunotherapy.

show abstract

“…The association between the intestinal microbiota and the effects of immune checkpoint inhibitors is an area of particular interest ( 50 ). An interesting study has endeavored to find a relationship between the intestinal microbiota and chronic pain ( 51 ), and we hope that such research will continue.…”

Section: Othersmentioning

confidence: 99%

Post-thoracotomy pain syndrome in the era of minimally invasive thoracic surgery

Miyazaki,

Doi,

Matsumoto

2024

J Thorac Dis

View full text Add to dashboard Cite

Post-thoracotomy pain syndrome (PTPS) is defined as pain around the wound that persists for more than 2 months after surgery. Persistent pain not only increases the use of analgesics and their side effects but also causes many social problems, such as decreased activities of daily living, decreased quality of life, and increased medical costs. In particular, thoracic surgery is associated with a higher frequency and severity of chronic pain than is surgery for other diseases. The basic principles of postoperative pain treatment, not limited to thoracic surgery, are multimodal analgesic methods (using combinations of several drugs to minimize opioid use) and around-the-clock treatment (administering analgesics at a fixed time and in sufficient doses). Thoracic surgeons must always be aware of the following three points: acute severe postoperative pain is a major risk factor for chronic pain; neuropathic pain due to intercostal nerve injury is a major cause of postoperative pain after thoracic surgery, and its presence must not be overlooked from the acute stage; and analgesics must be administered in sufficient quantities according to dosage and volume. The frequency of PTPS has decreased compared with that in the standard thoracotomy era because of the development of analgesia and the widespread use of minimally invasive procedures such as thoracoscopic surgery and robot-assisted surgery. However, no consistently effective prevention or treatment strategies for PTPS have yet been established. In this review, we focus on PTPS in the era of minimally invasive surgery and discuss the role of thoracic surgeons in its management.

show abstract

The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer

Cited by 6 publications

References 105 publications

Biomarkers of Immunotherapy Response in Patients with Non-Small-Cell Lung Cancer: Microbiota Composition, Short-Chain Fatty Acids, and Intestinal Permeability

Biomarkers of Immunotherapy Response in Patients with Non-Small-Cell Lung Cancer: Microbiota Composition, Short-Chain Fatty Acids, and Intestinal Permeability

Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC)

Post-thoracotomy pain syndrome in the era of minimally invasive thoracic surgery

Contact Info

Product

Resources

About